These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 23211054)

  • 21. Evaluation of progression markers in the premotor phase of Parkinson's disease: the progression markers in the premotor phase study.
    Liepelt-Scarfone I; Gauss K; Maetzler W; Müller K; Bormann C; Fruhmann Berger M; Timmers M; Streffer J; Berg D
    Neuroepidemiology; 2013; 41(3-4):174-82. PubMed ID: 24051361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. When does Parkinson's disease begin?
    Gaig C; Tolosa E
    Mov Disord; 2009; 24 Suppl 2():S656-64. PubMed ID: 19877243
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biomarkers of Parkinson's Disease: An Introduction.
    Titova N; Qamar MA; Chaudhuri KR
    Int Rev Neurobiol; 2017; 132():183-196. PubMed ID: 28554407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biomarkers for Parkinson's Disease: Recent Advancement.
    Lotankar S; Prabhavalkar KS; Bhatt LK
    Neurosci Bull; 2017 Oct; 33(5):585-597. PubMed ID: 28936761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biomarkers for the diagnosis and management of Parkinson's disease.
    Waragai M; Sekiyama K; Fujita M; Tokuda T; Hashimoto M
    Expert Opin Med Diagn; 2013 Jan; 7(1):71-83. PubMed ID: 23530844
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biomarkers in Parkinson's disease: Advances and strategies.
    Delenclos M; Jones DR; McLean PJ; Uitti RJ
    Parkinsonism Relat Disord; 2016 Jan; 22 Suppl 1(Suppl 1):S106-10. PubMed ID: 26439946
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biomarkers of Parkinson's disease and Dementia with Lewy bodies.
    Henchcliffe C; Dodel R; Beal MF
    Prog Neurobiol; 2011 Dec; 95(4):601-13. PubMed ID: 21983334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease].
    Hattori N
    Rinsho Shinkeigaku; 2004; 44(4-5):241-62. PubMed ID: 15287506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.
    Mollenhauer B; Parnetti L; Rektorova I; Kramberger MG; Pikkarainen M; Schulz-Schaeffer WJ; Aarsland D; Svenningsson P; Farotti L; Verbeek MM; Schlossmacher MG
    J Neurochem; 2016 Oct; 139 Suppl 1():290-317. PubMed ID: 26452984
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Role of Salivary Biomarkers in the Early Diagnosis of Alzheimer's Disease and Parkinson's Disease.
    Pawlik P; Błochowiak K
    Diagnostics (Basel); 2021 Feb; 11(2):. PubMed ID: 33671562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Concept of Prodromal Parkinson's Disease.
    Mahlknecht P; Seppi K; Poewe W
    J Parkinsons Dis; 2015; 5(4):681-97. PubMed ID: 26485429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imaging Markers of Progression in Parkinson's Disease.
    Strafella AP; Bohnen NI; Pavese N; Vaillancourt DE; van Eimeren T; Politis M; Tessitore A; Ghadery C; Lewis S;
    Mov Disord Clin Pract; 2018; 5(6):586-596. PubMed ID: 30637278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In search of Parkinson's disease biomarkers - is the answer in our mouths? A systematic review of the literature on salivary biomarkers of Parkinson's disease.
    Figura M; Friedman A
    Neurol Neurochir Pol; 2020; 54(1):14-20. PubMed ID: 32003440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging role of S100B protein implication in Parkinson's disease pathogenesis.
    Angelopoulou E; Paudel YN; Piperi C
    Cell Mol Life Sci; 2021 Feb; 78(4):1445-1453. PubMed ID: 33052436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cerebrospinal Fluid Biomarkers for Target Engagement and Efficacy in Clinical Trials for Alzheimer's and Parkinson's Diseases.
    Parnetti L; Eusebi P; Lleó A
    Front Neurol Neurosci; 2016; 39():117-23. PubMed ID: 27463974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current advances in metabolomic studies on non-motor psychiatric manifestations of Parkinson's disease (Review).
    Ciobanu AM; Ionita I; Buleandra M; David IG; Popa DE; Ciucu AA; Budisteanu M
    Exp Ther Med; 2021 Sep; 22(3):1010. PubMed ID: 34345292
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression.
    Fereshtehnejad SM; Zeighami Y; Dagher A; Postuma RB
    Brain; 2017 Jul; 140(7):1959-1976. PubMed ID: 28549077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advances in Biomarker Research in Parkinson's Disease.
    Mehta SH; Adler CH
    Curr Neurol Neurosci Rep; 2016 Jan; 16(1):7. PubMed ID: 26711276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biomarkers of Parkinson's disease: current status and future perspectives.
    Wang J; Hoekstra JG; Zuo C; Cook TJ; Zhang J
    Drug Discov Today; 2013 Feb; 18(3-4):155-62. PubMed ID: 22982303
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation.
    Latourelle JC; Beste MT; Hadzi TC; Miller RE; Oppenheim JN; Valko MP; Wuest DM; Church BW; Khalil IG; Hayete B; Venuto CS
    Lancet Neurol; 2017 Nov; 16(11):908-916. PubMed ID: 28958801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.